|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
19,370,000 |
Market
Cap: |
776.74(K) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.0401 - $1.8 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Aravive is a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of diseases, including cancer and fibrosis. Co.'s primary product candidate, batiraxcept, is a decoy protein that targets the GAS6-AXL signaling pathway. By capturing serum GAS6, batiraxcept starves the AXL pathway of its signal, potentially halting the biological programming that promotes disease progression. AXL receptor signaling plays a role in multiple types of malignancies by promoting metastasis, cancer cell survival, resistance to treatments, and immune suppression.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Malik Shahzad |
Director |
|
2015-01-22 |
4 |
B |
$17.25 |
$948,750 |
I/I |
55,000 |
2,271,558 |
2.1 |
- |
|
Cleland Jeffrey L |
President and CEO |
|
2015-01-12 |
4 |
AS |
$22.85 |
$91,418 |
D/D |
(4,000) |
117,432 |
|
- |
|
Cleland Jeffrey L |
President and CEO |
|
2015-01-05 |
4 |
AS |
$21.29 |
$87,741 |
D/D |
(4,000) |
121,432 |
|
- |
|
Westberg Paul |
Sr. VP, Business Development |
|
2015-01-05 |
4 |
AS |
$22.19 |
$112,401 |
D/D |
(5,000) |
22,487 |
|
- |
|
Westberg Paul |
Sr. VP, Business Development |
|
2015-01-05 |
4 |
OE |
$1.27 |
$6,325 |
D/D |
5,000 |
27,487 |
|
- |
|
Cleland Jeffrey L |
President and CEO |
|
2014-12-29 |
4 |
AS |
$22.11 |
$88,422 |
D/D |
(4,000) |
125,432 |
|
- |
|
Westberg Paul |
Sr. VP, Business Development |
|
2014-12-26 |
4 |
A |
$0.00 |
$0 |
D/D |
3,797 |
22,487 |
|
- |
|
Cleland Jeffrey L |
President and CEO |
|
2014-12-26 |
4 |
A |
$0.00 |
$0 |
D/D |
32,160 |
129,432 |
|
- |
|
Brumm Joshua T |
Chief Financial Officer |
|
2014-12-26 |
4 |
A |
$0.00 |
$0 |
D/D |
10,445 |
36,635 |
|
- |
|
Cleland Jeffrey L |
President and CEO |
|
2014-12-22 |
4/A |
AS |
$20.54 |
$168,692 |
D/D |
(7,980) |
133,388 |
|
- |
|
Cleland Jeffrey L |
President and CEO |
|
2014-12-22 |
4 |
AS |
$20.54 |
$168,692 |
D/D |
(7,980) |
97,272 |
|
- |
|
Cleland Jeffrey L |
President and CEO |
|
2014-12-19 |
4/A |
AS |
$20.00 |
$400 |
D/D |
(20) |
141,368 |
|
- |
|
Cleland Jeffrey L |
President and CEO |
|
2014-12-19 |
4 |
AS |
$20.00 |
$400 |
D/D |
(20) |
105,252 |
|
- |
|
Ratcliffe Liam |
10% Owner |
|
2014-12-18 |
4 |
S |
$19.01 |
$2,851,845 |
D/D |
(150,000) |
2,409,374 |
|
- |
|
Cleland Jeffrey L |
President and CEO |
|
2014-12-15 |
4 |
A |
$0.00 |
$0 |
D/D |
496 |
142,396 |
|
- |
|
Westberg Paul |
Sr. VP, Business Development |
|
2014-12-12 |
4 |
AS |
$18.65 |
$56,970 |
D/D |
(3,054) |
18,690 |
|
- |
|
Westberg Paul |
Sr. VP, Business Development |
|
2014-12-12 |
4 |
OE |
$1.27 |
$3,863 |
D/D |
3,054 |
21,744 |
|
- |
|
Westberg Paul |
Sr. VP, Business Development |
|
2014-12-11 |
4 |
AS |
$18.51 |
$128,570 |
D/D |
(6,946) |
18,690 |
|
- |
|
Westberg Paul |
Sr. VP, Business Development |
|
2014-12-11 |
4 |
OE |
$1.27 |
$8,787 |
D/D |
6,946 |
25,636 |
|
- |
|
Greer R Scott |
Director |
|
2014-12-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
5,000 |
|
- |
|
Yucca (jersey) Slp |
10% Owner |
|
2014-11-24 |
4 |
S |
$18.02 |
$310,008 |
D/D |
(17,207) |
19,161 |
|
- |
|
Index Ventures Iv Parallel Entrepreneur Fund (jers |
10% Owner |
|
2014-11-21 |
4 |
S |
$18.04 |
$483,314 |
D/D |
(26,793) |
19,299 |
|
- |
|
Yucca (jersey) Slp |
10% Owner |
|
2014-11-20 |
4 |
S |
$18.32 |
$164,885 |
D/D |
(9,000) |
19,513 |
|
- |
|
Yucca (jersey) Slp |
10% Owner |
|
2014-11-18 |
4 |
S |
$19.38 |
$3,709,036 |
D/D |
(191,362) |
19,585 |
|
- |
|
Cleland Jeffrey L |
President and CEO |
|
2014-11-14 |
4/A |
GD |
$0.00 |
$0 |
D/D |
1,900 |
141,388 |
|
- |
|
258 Records found
|
|
Page 10 of 11 |
|
|